Weekly chemo could be easier on elderly sarcoma patients

NCT ID NCT07125183

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving the chemotherapy drug doxorubicin weekly at a lower dose is effective and easier to tolerate for people aged 65 to 100 with advanced leiomyosarcoma, a type of soft tissue cancer. The standard dose often causes harsh side effects, especially in older or frailer patients. Researchers will track how long the cancer stays under control and how patients feel during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxorubicin (a chemotherapy drug)
What this could lead to: If successful, this could offer a better-tolerated chemotherapy option for elderly patients with advanced leiomyosarcoma, potentially improving quality of life while controlling tumor growth.
What could go wrong: This is a small early-phase trial with only 20 participants, so results may not apply broadly. The lower dose may also be less effective at stopping cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyosarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

University Of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.